Predictive value of C-reactive protein/albumin ratio for no-reflow in patients with non-ST-elevation myocardial infarction.
Aydın Rodi TosuTufan ÇınarMuhsin KalyoncuoğluHalil İbrahim BiterSinem ÇakalBeytullah ÇakalMurat SelçukErdal BelenMehmet Mustafa CanPublished in: Journal of cardiovascular and thoracic research (2022)
Introduction: The focus of this research was to explore the link between CRP (C-reactive protein) /albumin ratio (CAR), a novel inflammatory response marker, and no-reflow (NR) phenomena in non-ST elevation myocardial infarction (non-STEMI) patients during percutaneous coronary intervention (PCI). Methods: The current study recruited 209 non-STEMI participants who underwent PCI. The patients were divided into two groups based on their post-intervention Thrombolysis in Myocardial Infarction (TIMI) flow grade; those with and without NR. Results: In all, 30 non-STEMI patients (6.9%) had NR after PCI. CAR values were substantially greater in the NR group. The CAR was identified to be a determinant of the NR (OR: 1.250, 95% CI: 1.033-1.513, P =0.02), although CRP and albumin were not independently related with NR in the multivariate analysis. In our investigation, low density lipoprotein-cholesterol levels and high thrombus burden were also predictors of the occurrence of NR. According to receiver operating characteristic curve evaluation, the optimal value of CAR was>1.4 with 60% sensitivity and 47% specificity in detecting NR in non-STEMI patients following PCI. Conclusion: To the best of knowledge, this is the first investigation to demonstrate that the CAR, a new and useful inflammatory marker, can be utilized as a predictor of NR in patients with non-STEMI prior to PCI.
Keyphrases
- st elevation myocardial infarction
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- end stage renal disease
- coronary artery disease
- acute coronary syndrome
- acute myocardial infarction
- ejection fraction
- antiplatelet therapy
- coronary artery bypass grafting
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- pulmonary embolism
- heart failure
- risk assessment
- patient reported outcomes
- toll like receptor